Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Capsugel Flexes Breadth Of Capabilities In Development Collaborations

This article was originally published in The Tan Sheet

Executive Summary

Amit Patel, president of Capsugel’s Dosage Form Solutions business unit, says the firm is able to work more closely with customers in the product development process since it is no longer a subsidiary of Pfizer. Capsugel announced the launch of its Lipidex integrated technology platform June 5.

You may also be interested in...



New Parent Lonza Welcomes Capsugel's Independent Streak To Innovate

Lonza acquires Capsugel for $5.5bn cash, nearly twice as much as private equity firm KKR paid Pfizer for it, to enhance its product development and expand the market for its contract development and manufacturing services for drug and nutritional products.

New Parent Lonza Welcomes Capsugel's Independent Streak To Innovate

Lonza acquires Capsugel for $5.5bn cash, nearly twice as much as private equity firm KKR paid Pfizer for it, to enhance its product development and expand the market for its contract development and manufacturing services for drug and nutritional products.

Industry Roundup: Capsugel Expands, NAD On Lactation Claims, FitLife Kaniwa Extraction

Capsugel expands in Edinburgh; Motherlove lactation supplement claims unsupported; FitLife extracts kaniwa protein; and more news in brief.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106452

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel